Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Gains from Investment Securities (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Gains from Investment Securities data on record, last reported at $106000.0 in Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 71.66% year-over-year to $106000.0; the TTM value through Dec 2025 reached $383000.0, down 58.55%, while the annual FY2025 figure was $383000.0, 58.55% down from the prior year.
  • Gains from Investment Securities reached $106000.0 in Q4 2025 per VRCA's latest filing, up from $94000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $374000.0 in Q4 2024 and bottomed at $1000.0 in Q2 2021.
  • Average Gains from Investment Securities over 5 years is $89266.7, with a median of $85000.0 recorded in 2025.
  • Peak YoY movement for Gains from Investment Securities: soared 1526.09% in 2024, then crashed 71.66% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $2000.0 in 2021, then changed by 0.0% to $2000.0 in 2022, then soared by 1050.0% to $23000.0 in 2023, then skyrocketed by 1526.09% to $374000.0 in 2024, then plummeted by 71.66% to $106000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $106000.0 in Q4 2025, $94000.0 in Q3 2025, and $85000.0 in Q2 2025.